S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94

IntelGenx Technologies Stock Forecast, Price & News

+0.14 (+32.56 %)
(As of 10/15/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume2.86 million shs
Average Volume265,425 shs
Market Capitalization$63.84 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive IGXT News and Ratings via Email

Sign-up to receive the latest news and ratings for IntelGenx Technologies and its competitors with MarketBeat's FREE daily newsletter.

IntelGenx Technologies logo

About IntelGenx Technologies

IntelGenx Technologies Corp. is a oral drug delivery company, which focuses on the development and manufacturing of pharmaceutical oral films based on its proprietary VersaFilm technology platform. Its products include rizaport, tadalafil, loxapine, and montelukast. The company also offers a comprehensive portfolio of pharmaceutical services, such as pharmaceutical research & development, clinical monitoring, regulatory support, tech transfer & manufacturing scale-up and commercial manufacturing. IntelGenx Technologies was founded on July 27, 1999 and is headquartered in Ville Saint-Laurent, Canada.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$1.54 million
Book Value
($0.01) per share


Net Income
$-7.04 million
Net Margins




Market Cap
$63.84 million
Next Earnings Date
11/11/2021 (Estimated)
Not Optionable


Overall MarketRank

1.05 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

IntelGenx Technologies (OTCMKTS:IGXT) Frequently Asked Questions

What stocks does MarketBeat like better than IntelGenx Technologies?

Wall Street analysts have given IntelGenx Technologies a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but IntelGenx Technologies wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting IntelGenx Technologies?

IntelGenx Technologies saw a increase in short interest during the month of September. As of September 30th, there was short interest totaling 27,700 shares, an increase of 31.3% from the September 15th total of 21,100 shares. Based on an average trading volume of 230,000 shares, the short-interest ratio is presently 0.1 days.
View IntelGenx Technologies' Short Interest

When is IntelGenx Technologies' next earnings date?

IntelGenx Technologies is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for IntelGenx Technologies

How were IntelGenx Technologies' earnings last quarter?

IntelGenx Technologies Corp. (OTCMKTS:IGXT) posted its quarterly earnings data on Wednesday, August, 4th. The company reported ($0.02) EPS for the quarter. The firm had revenue of $0.16 million for the quarter. IntelGenx Technologies had a negative net margin of 422.71% and a negative trailing twelve-month return on equity of 1,071.26%.
View IntelGenx Technologies' earnings history

How has IntelGenx Technologies' stock been impacted by Coronavirus?

IntelGenx Technologies' stock was trading at $0.3950 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, IGXT shares have increased by 44.3% and is now trading at $0.57.
View which stocks have been most impacted by COVID-19

Who are IntelGenx Technologies' key executives?

IntelGenx Technologies' management team includes the following people:
  • Horst G. Zerbe, Chairman & Chief Executive Officer
  • André Godin, President & Chief Financial Officer
  • Rodolphe Obeid, Chief Operating Officer
  • Nadine Paiement, Vice President-Research & Development
  • Dana Matzen, Vice President-Business & Corporate Development

What other stocks do shareholders of IntelGenx Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IntelGenx Technologies investors own include Cronos Group (CRON), KemPharm (KMPH), Exelixis (EXEL), SemiLEDs (LEDS), New Residential Investment (NRZ), Anavex Life Sciences (AVXL), Ampio Pharmaceuticals (AMPE), BioDelivery Sciences International (BDSI), BIOLASE (BIOL) and Ocugen (OCGN).

What is IntelGenx Technologies' stock symbol?

IntelGenx Technologies trades on the OTCMKTS under the ticker symbol "IGXT."

How do I buy shares of IntelGenx Technologies?

Shares of IGXT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IntelGenx Technologies' stock price today?

One share of IGXT stock can currently be purchased for approximately $0.57.

How much money does IntelGenx Technologies make?

IntelGenx Technologies has a market capitalization of $63.84 million and generates $1.54 million in revenue each year. The company earns $-7.04 million in net income (profit) each year or ($0.07) on an earnings per share basis.

How many employees does IntelGenx Technologies have?

IntelGenx Technologies employs 4 workers across the globe.

What is IntelGenx Technologies' official website?

The official website for IntelGenx Technologies is www.intelgenx.com.

Where are IntelGenx Technologies' headquarters?

IntelGenx Technologies is headquartered at 6420 ABRAMS, VILLE SAINT LAURENT A8, H4S 1Y2.

How can I contact IntelGenx Technologies?

IntelGenx Technologies' mailing address is 6420 ABRAMS, VILLE SAINT LAURENT A8, H4S 1Y2. The company can be reached via phone at (514) 331-7440 or via email at [email protected].

This page was last updated on 10/16/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.